Cardiomyopathy (CM) Program in Pharmaceutical Benefits Scheme (PBS) 012-24041204

CM restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS CM restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial authority application form (PB360)

Symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial grandfather authority application form (PB361)

Transthyretin amyloid cardiomyopathy - tafamidis - initial authority application form (PB358)

Services Australia website

Cardiomyopathy

External websites

PBS schedule for:

FAQs from Service Officers

Table 1: for FAQs about all Complex programs, see Table 2 in Processing Complex Authority Required Listings.

Item	Description
1	If a grandfather patient has not had at least 6 months on optimal dose of mavacamten, will their prescriber need to apply under the first continuing or the second continuing after the grandfather approval? Prescribers must apply under the first continuing for dose adjustment. If the patient has had at least 6 months on optimal dose, prescribers must apply under the subsequent continuing restriction after the grandfather approval.
2	If a change of dose in mavacamten is required after an initial is approved but before 12 weeks, can the change of dose be approved under the first continuing treatment? Yes.
3	Can a patient have multiple first continuing approvals of different strengths of mavacamten until they can achieve a stable dose? Yes. The patient’s authorities remain being approved as the first continuing until they are stable on the same dose for a period of 6 months. As such, they can have multiple first continuing approvals of different strengths until a stable dose is achieved.